Spots Global Cancer Trial Database for A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Official Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Study ID: NCT02432326
Study Description
Brief Summary: This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Weill Cornell Medical College, New York, New York, United States
Texas Oncology - Austin Midtown, Austin, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Texas Oncology - Fort Worth 12th Ave, Fort Worth, Texas, United States
Texas Oncology, P.A., San Antonio, Texas, United States
Texas Oncology, P.A., San Antonio, Texas, United States
Texas Oncology - Tyler, Tyler, Texas, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Northwest Cancer Specialists, PC, Vancouver, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
